Conway Vikki L 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 7, 2024
Insider Transaction Report
Form 4
Conway Vikki L
See "Remarks"
Transactions
- Exercise/Conversion
Ordinary Shares
2024-03-05+4,954→ 16,646 total - Sale
Ordinary Shares
2024-03-05$13.52/sh−1,427$19,286→ 15,219 total - Exercise/Conversion
Restricted Share Units
2024-03-05−4,954→ 4,957 total→ Ordinary Shares (4,954 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 5, 2021, with 4,954 vesting on March 5, 2024, and 4,957 vesting on March 5, 2025.